Featured Research

from universities, journals, and other organizations

Long-term Hormone Replacement Therapy Increases Breast Cancer Risk Until 5 Years After Use, Study Finds

Date:
May 30, 2008
Source:
Helmholtz Association of German Research Centres
Summary:
Now there is proof for women in Germany, too: If hormone replacement therapy is taken over a period of more than five years, the risk of breast cancer will increase. While this risk is considerably elevated during use of hormone medication, it drops back to the original level within about five years after a woman has stopped taking hormones.

If hormone replacement therapy is taken over a period of more than five years, the risk of breast cancer will increase. While this risk is considerably elevated during use of hormone medication, it drops back to the original level within about five years after a woman has stopped taking hormones. These new findings from Germany fit with earlier findings in the U.S.

"Are you taking or did you take hormones? If yes, which hormone medication and for how long? When did you stop taking hormone replacement medication?" 3,464 breast cancer patients and 6,657 healthy women between the ages of 50 and 74 years participated in a large survey and elicited detailed information about hormone replacement medications they are taking or used to take for relief of menopausal symptoms.

The survey was prompted by the "MARIE" case-control study carried out by the German Cancer Research Center (DKFZ) and the University Hospitals in Hamburg-Eppendorf, Germany. The goal of this 6-year study, which was financed by the German Cancer Aid (Deutsche Krebshilfe), was to determine the effect of hormones -- both on their own and in association with other factors -- on breast cancer risk.

Women who have taken menopausal hormone therapy before have a 37 percent higher risk of breast cancer than women who have never taken hormone replacement therapy (HRT). During the actual time of HRT use the risk is even elevated by 73 percent. Within five years after cessation of therapy the risk of breast cancer in former HRT users falls back to the level of women who never used HRT. "These results of the MARIE study confirm findings of two U.S. and U.K. studies (Women's Health Initiative Study and Million Women Study) that caused a stir in 2002 and 2003," says Professor Dr. Wilhelm Braendle of Hamburg-Eppendorf University Hospitals, who headed the study.

"It has often been argued that the results of the U.S. study could not be applied to Germany where prescription practices are completely different. Therefore, we captured the various hormone preparations, especially the various progestins, very precisely. We have obtained similar results as the U.S. researchers," Professor Dr. Jenny Chang-Claude of DKFZ summarizes. "With our new data, we provide physicians in Germany with solid information that will help them to advise their patients about the benefits and risks of hormone replacement therapy."

The MARIE study also confirms that different hormone preparations have different effects: Compared to the risk of women who have never used HRT, a combined therapy of estrogen and progestin doubles the risk of breast cancer, while use of estrogen alone (estrogen replacement therapy) raises the risk by only 15 percent. However, in both cases the risk increases only if hormones are taken for more than five years.

"Hormone replacement therapy also appears to have a different influence on different types of breast cancer," Braendle explains. "The risk of developing one of the less common lobular or tubular breast cancers increases twice as much under HRT as the risk of the common type of ductal carcinoma, which constitutes 40 to 75 percent of all malignant tumors of the breast."


Story Source:

The above story is based on materials provided by Helmholtz Association of German Research Centres. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dieter Flesch-Janys, Tracy Slanger, Elke Mutschelknauss, Silke Kropp,Nadia Obi, Eik Vettorazzi, Wilhelm Braendle, Gunter Bastert, Stefan Hentschel, Jόrgen Berger, and Jenny Chang-Claude. Risk of Different Histological Types of Postmenopausal Breast Cancer by Type and Regimen of Menopausal Hormone Therapy. International Journal of Cancer, 2008 DOI: 10.1002/ijc.23655

Cite This Page:

Helmholtz Association of German Research Centres. "Long-term Hormone Replacement Therapy Increases Breast Cancer Risk Until 5 Years After Use, Study Finds." ScienceDaily. ScienceDaily, 30 May 2008. <www.sciencedaily.com/releases/2008/05/080528102922.htm>.
Helmholtz Association of German Research Centres. (2008, May 30). Long-term Hormone Replacement Therapy Increases Breast Cancer Risk Until 5 Years After Use, Study Finds. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/05/080528102922.htm
Helmholtz Association of German Research Centres. "Long-term Hormone Replacement Therapy Increases Breast Cancer Risk Until 5 Years After Use, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2008/05/080528102922.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins